Sirolimus, a compound that inhibits mTOR signalling, is being studied to treat plexiform neurofibromas.The combination of erlotinib with sirolimus was studied to treat low-grade gliomas.Early research has shown potential for using the c-kit tyrosine kinase blocking properties of imatinib to treat plexiform neurofibromas.Peginterferon alfa-2b is being studied to treat plexiform neurofibromas.Sorafenib is being studied for treatment of unresectable plexiform neurofibroma and low-grade astrocytomas.In vitro, tranilast, inhibits growth of neurofibroma cells.Gene therapy for the neurofibromin 1 gene represents the ultimate solution to preventing the cluster of maladies which are enabled by the mutation. As of 2006, therapy for NF1 tumors had not been tested due to the lack of an appropriate NF1 tumor model. See also
Malignant peripheral nerve sheath tumor
Neurofibromatosis
Neurofibromin
Genetic disorder
Watson syndrome
Proteus syndrome
RASopathy
Palisaded encapsulated neuroma
Skin lesion
List of cutaneous conditions

References
External links

DermAtlas 67
"Neurofibroma" at Dorlands Medical Dictionary
Ferner RE, ODoherty MJ (December 2002). "Neurofibroma and schwannoma". Current Opinion in Neurology. 15 (6): 679–684. doi:10.1097/00019052-200212000-00004. PMID 12447105. S2CID 23782923.
Bladder outlet obstruction (or obstructive uropathy) occurs when urine is unable to flow from the kidneys through the ureters and out of the bladder through the urethra. Decreased flow of urine leads to swelling of the urinary tract, called hydronephrosis. This process of decreased flow of urine through the urinary tract can begin as early as during intrauterine life and it prevents normal development of fetal kidneys and fetal urine. Low levels of fetal urine leads to low amniotic fluid levels and incomplete lung maturation. Older children and adults can also experience bladder outlet obstruction; however, this process is usually reversible and isnt associated with as many poor outcomes as in infants with congenital bladder outlet obstruction. Causes
Bladder outlet obstruction is classified based on where along the urinary tract the obstruction occurs, including upper urinary tract obstruction and lower urinary tract obstruction. Depending on the location of the obstruction, one or both sides of the urinary tract will be involved. In approximately 50% of cases of congenital hydronephrosis, there is no known cause. In many cases, obstruction along the urinary tract in utero leads to some form of CAKUT mentioned above. Upper urinary tract obstruction
Upper urinary tract obstruction includes the renal pelvis and upper ureters. Ureteropelvic junction obstruction
Ureteropelvic junction obstruction (UPJ obstruction) is an obstruction at the level of the ureter and renal pelvis. It is the most common cause of hydronephrosis detected in utero and is the most common anomaly detected on prenatal ultrasounds.